Home › Funds › FCPM III SERVICES B.V. › NAMS
FCPM III SERVICES B.V. position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
FCPM III SERVICES B.V. reported holding 8,490,353 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$287.7M, representing 38.34% of its reported portfolio and ranking #1 among its reported holdings. FCPM III SERVICES B.V. has disclosed NAMS holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How FCPM III SERVICES B.V.'s NAMS position evolved
FCPM III SERVICES B.V. first disclosed a stake in NAMS in Q4 2023 at 11,831,461 shares (US$132.2M). The position peaked in Q4 2025 at 9,198,900 shares, worth US$322.7M. Across 11 filings, FCPM III SERVICES B.V. increased the stake 1 time(s), trimmed it 4 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 8,490,353 shares valued at US$287.7M — a reduction of -708,547 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 11.83M | $132.16M | New |
| Q1 2024 | 11.83M | $279.81M | Hold |
| Q2 2024 | 11.83M | $227.28M | Hold |
| Q3 2024 | 11.83M | $196.40M | Hold |
| Q4 2024 | 10.60M | $272.35M | Reduce |
| Q1 2025 | 10.94M | $223.85M | Add |
| Q2 2025 | 10.63M | $192.55M | Reduce |
| Q3 2025 | 9.21M | $262.00M | Reduce |
| Q4 2025 | 9.20M | $322.70M | Hold |
| Q1 2026 | 9.20M | $294.46M | Hold |
| Q2 2026 | 8.49M | $287.74M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 43 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.09M sh · $613.03M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $323.66M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.26M sh · $144.53M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 3.81M sh · $129.00M · Q2 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- MAVERICK CAPITAL LTD 3.27M sh · $110.75M · Q2 2026
- Duquesne Family Office LLC 3.07M sh · $104.05M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 2.21M sh · $74.85M · Q2 2026
- Castle Hook Partners LP 1.37M sh · $46.46M · Q2 2026
- NWI MANAGEMENT LP 702.00K sh · $23.79M · Q2 2026
- Rock Springs Capital Management LP 582.74K sh · $19.75M · Q2 2026
- First Turn Management, LLC 582.50K sh · $19.74M · Q2 2026
More on FCPM III SERVICES B.V.
FAQ
How long has FCPM III SERVICES B.V. held NAMS?
FCPM III SERVICES B.V. has disclosed NAMS holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is FCPM III SERVICES B.V.'s current position in NAMS?
As of Q2 2026, FCPM III SERVICES B.V. holds 8.49M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $287.74M, representing 38.34% of its reported portfolio and ranking #1.
Has FCPM III SERVICES B.V. been buying or selling NAMS?
In the latest 13F filing (Q2 2026), FCPM III SERVICES B.V. reduced its position in NAMS. The position peaked in Q4 2025 at 9.20M shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.